GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Canbridge Pharmaceuticals Inc (FRA:MF1) » Definitions » Unpaid Loss & Loss Reserve

Canbridge Pharmaceuticals (FRA:MF1) Unpaid Loss & Loss Reserve


View and export this data going back to 2022. Start your Free Trial

What is Canbridge Pharmaceuticals Unpaid Loss & Loss Reserve?

Unpaid Loss & Loss Reserve only applies to insurance companies.


Canbridge Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Building 21, No. 388 Xinping Street, Unit 18, 6th Floor, Suzhou Industrial Park, Suzhou, CHN
Canbridge Pharmaceuticals Inc is a biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.